CryoLife spins off fibrin sealant development company
This article was originally published in Clinica
CryoLife has set up a separate company, AuraZyme Pharmaceuticals, to speed up development of its light-activated fibrin sealant, FibRx, without putting too much strain on the company balance sheet.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.